

# Sook Wah Yee

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1495764/publications.pdf>

Version: 2024-02-01

66  
papers

6,390  
citations

126907

33  
h-index

128289

60  
g-index

69  
all docs

69  
docs citations

69  
times ranked

7899  
citing authors

#	ARTICLE	IF	CITATIONS
1	Membrane transporters in drug development. <i>Nature Reviews Drug Discovery</i> , 2010, 9, 215-236.	46.4	2,886
2	SLC transporters as therapeutic targets: emerging opportunities. <i>Nature Reviews Drug Discovery</i> , 2015, 14, 543-560.	46.4	584
3	OCT1 is a high-capacity thiamine transporter that regulates hepatic steatosis and is a target of metformin. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 9983-9988.	7.1	203
4	Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin. <i>Pharmacogenetics and Genomics</i> , 2009, 19, 497-504.	1.5	202
5	Variation in the glucose transporter gene SLC2A2 is associated with glycemic response to metformin. <i>Nature Genetics</i> , 2016, 48, 1055-1059.	21.4	165
6	The Clinical Pharmacogenetics Implementation Consortium Guideline for <i>SLCO1B1</i> , <i>ABCG2</i> , and <i>CYP2C9</i> genotypes and Statin-Associated Musculoskeletal Symptoms. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 1007-1021.	4.7	120
7	A genome-wide association study of bronchodilator response in Latinos implicates rare variants. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, 370-378.e15.	2.9	105
8	Organic Anion Transporter 2 ( <i>SLC22A7</i> ) Is a Facilitative Transporter of cGMP. <i>Molecular Pharmacology</i> , 2008, 73, 1151-1158.	2.3	103
9	Comparison of human solute carriers. <i>Protein Science</i> , 2010, 19, 412-428.	7.6	99
10	Influence of Transporter Polymorphisms on Drug Disposition and Response: A Perspective From the International Transporter Consortium. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 803-817.	4.7	99
11	Genetic variants in multidrug and toxic compound extrusion-1, hMATE1, alter transport function. <i>Pharmacogenomics Journal</i> , 2009, 9, 127-136.	2.0	94
12	Targeted Disruption of Organic Cation Transporter 3 Attenuates the Pharmacologic Response to Metformin. <i>Molecular Pharmacology</i> , 2015, 88, 75-83.	2.3	88
13	Genome-wide association studies of drug response and toxicity: an opportunity for genome medicine. <i>Nature Reviews Drug Discovery</i> , 2017, 16, 70-70.	46.4	80
14	Potent CYP19 (Aromatase) 1-[(Benzofuran-2-yl)(phenylmethyl)pyridine, -imidazole, and -triazole Inhibitors: Synthesis and Biological Evaluation. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 1016-1022.	6.4	79
15	Metformin Is a Substrate and Inhibitor of the Human Thiamine Transporter, THTR-2 (SLC19A3). <i>Molecular Pharmaceutics</i> , 2015, 12, 4301-4310.	4.6	79
16	Organic Cation Transporters Modulate the Uptake and Cytotoxicity of Picoplatin, a Third-Generation Platinum Analogue. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 1058-1069.	4.1	74
17	Discovery of Competitive and Noncompetitive Ligands of the Organic Cation Transporter 1 (OCT1); Tj ETQq1 1 0.784314 rgBT /Overlaid	6.4	58
18	Identification and characterization of novel polymorphisms in the basal promoter of the human transporter, MATE1. <i>Pharmacogenetics and Genomics</i> , 2009, 19, 770-780.	1.5	56

#	ARTICLE	IF	CITATIONS
19	Rapid Method To Determine Intracellular Drug Concentrations in Cellular Uptake Assays: Application to Metformin in Organic Cation Transporter 1-Transfected Human Embryonic Kidney 293 Cells. <i>Drug Metabolism and Disposition</i> , 2016, 44, 356-364.	3.3	54
20	Organic Anion Transporter Polypeptide 1B1 Polymorphism Modulates the Extent of Drug-Drug Interaction and Associated Biomarker Levels in Healthy Volunteers. <i>Clinical and Translational Science</i> , 2019, 12, 388-399.	3.1	53
21	Pharmacogenomics of membrane transporters: past, present and future. <i>Pharmacogenomics</i> , 2010, 11, 475-479.	1.3	49
22	Reduced Renal Clearance of Cefotaxime in Asians with a Low-Frequency Polymorphism of OAT3 (SLC22A8). <i>Journal of Pharmaceutical Sciences</i> , 2013, 102, 3451-3457.	3.3	47
23	The Effect of Famotidine, a MATE1-Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin. <i>Clinical Pharmacokinetics</i> , 2016, 55, 711-721.	3.5	47
24	The role of ATM in response to metformin treatment and activation of AMPK. <i>Nature Genetics</i> , 2012, 44, 359-360.	21.4	46
25	Organic cation transporter 1 (OCT1) modulates multiple cardiometabolic traits through effects on hepatic thiamine content. <i>PLoS Biology</i> , 2018, 16, e2002907.	5.6	45
26	Inhibition of Vitamin D3 metabolism enhances VDR signalling in androgen-independent prostate cancer cells. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2006, 98, 228-235.	2.5	42
27	Novel Tetralone-Derived Retinoic Acid Metabolism Blocking Agents: Synthesis and in Vitro Evaluation with Liver Microsomal and MCF-7 CYP26A1 Cell Assays. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 7123-7131.	6.4	41
28	Organic cation transporter 3 (OCT3) is a distinct catecholamines clearance route in adipocytes mediating the beiging of white adipose tissue. <i>PLoS Biology</i> , 2019, 17, e2006571.	5.6	41
29	Genomic Characterization of Metformin Hepatic Response. <i>PLoS Genetics</i> , 2016, 12, e1006449.	3.5	41
30	Molecular Mechanisms for Species Differences in Organic Anion Transporter 1, OAT1: Implications for Renal Drug Toxicity. <i>Molecular Pharmacology</i> , 2018, 94, 689-699.	2.3	40
31	Functional Genetic Variation in the Basal Promoter of the Organic Cation/Carnitine Transporters OCTN1 ( <i>SLC22A4</i> ) and OCTN2 ( <i>SLC22A5</i> ). <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2009, 329, 262-271.	2.5	38
32	Impact of polymorphisms in drug pathway genes on disease-free survival in adults with acute myeloid leukemia. <i>Journal of Human Genetics</i> , 2013, 58, 353-361.	2.3	38
33	Genomewide Association Studies in Pharmacogenomics. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 637-648.	4.7	38
34	Synthesis and CYP26A1 inhibitory activity of 1-[benzofuran-2-yl-(4-alkyl/aryl-phenyl)-methyl]-1H-triazoles. <i>Bioorganic and Medicinal Chemistry</i> , 2006, 14, 3643-3653.	3.0	37
35	Prediction and validation of enzyme and transporter off-targets for metformin. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2015, 42, 463-475.	1.8	37
36	Genetic Variation in the Proximal Promoter of ABC and SLC Superfamilies: Liver and Kidney Specific Expression and Promoter Activity Predict Variation. <i>PLoS ONE</i> , 2009, 4, e6942.	2.5	34

#	ARTICLE	IF	CITATIONS
37	Synthesis and CYP24 inhibitory activity of 2-substituted-3,4-dihydro-2H-naphthalen-1-one (tetralone) derivatives. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2004, 14, 5651-5654.	2.2	32
38	Genetic Variants in <i>CPA6</i> and <i>PRPF31</i> Are Associated With Variation in Response to Metformin in Individuals With Type 2 Diabetes. <i>Diabetes</i> , 2018, 67, 1428-1440.	0.6	32
39	Identification and Characterization of Proximal Promoter Polymorphisms in the Human Concentrative Nucleoside Transporter 2 ( <i>SLC28A2</i> ). <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2009, 328, 699-707.	2.5	30
40	SLC19A1 pharmacogenomics summary. <i>Pharmacogenetics and Genomics</i> , 2010, 20, 708-715.	1.5	28
41	Pharmacometabolomic Assessment of Metformin in Non-diabetic, African Americans. <i>Frontiers in Pharmacology</i> , 2016, 7, 135.	3.5	28
42	GenEpi: gene-based epistasis discovery using machine learning. <i>BMC Bioinformatics</i> , 2020, 21, 68.	2.6	25
43	Computational Discovery and Experimental Validation of Inhibitors of the Human Intestinal Transporter OATP2B1. <i>Journal of Chemical Information and Modeling</i> , 2017, 57, 1402-1413.	5.4	23
44	Unraveling the functional role of the orphan solute carrier, SLC22A24 in the transport of steroid conjugates through metabolomic and genome-wide association studies. <i>PLoS Genetics</i> , 2019, 15, e1008208.	3.5	23
45	Genome-Wide Association and Functional Studies Reveal Novel Pharmacological Mechanisms for Allopurinol. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 623-631.	4.7	23
46	Genome-Wide Meta-analysis Identifies Genetic Variants Associated With Glycemic Response to Sulfonylureas. <i>Diabetes Care</i> , 2021, 44, 2673-2682.	8.6	23
47	Deorphaning a solute carrier 22 family member, SLC22A15, through functional genomic studies. <i>FASEB Journal</i> , 2020, 34, 15734-15752.	0.5	21
48	Synthesis and CYP24A1 inhibitory activity of N-(2-(1H-imidazol-1-yl)-2-phenylethyl)arylamides. <i>Bioorganic and Medicinal Chemistry</i> , 2010, 18, 4939-4946.	3.0	19
49	Pharmacogene regulatory elements: from discovery to applications. <i>Genome Medicine</i> , 2012, 4, 45.	8.2	18
50	Drugs in COVID-19 Clinical Trials: Predicting Transporter-Mediated Drug-Drug Interactions Using In Vitro Assays and Real-World Data. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 108-122.	4.7	16
51	New and Emerging Research on Solute Carrier and ATP Binding Cassette Transporters in Drug Discovery and Development: Outlook From the International Transporter Consortium. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 540-561.	4.7	16
52	OCT1 in hepatic steatosis and thiamine disposition. <i>Cell Cycle</i> , 2015, 14, 283-284.	2.6	15
53	Functional and structural analysis of rare SLC2A2 variants associated with Fanconi-Bickel syndrome and metabolic traits. <i>Human Mutation</i> , 2019, 40, 983-995.	2.5	13
54	High Throughput Screening of a Prescription Drug Library for Inhibitors of Organic Cation Transporter 3, OCT3. <i>Pharmaceutical Research</i> , 2022, 39, 1599-1613.	3.5	13

#	ARTICLE	IF	CITATIONS
55	Pharmacogenetics of Antidiabetic Drugs. <i>Advances in Pharmacology</i> , 2018, 83, 361-389.	2.0	12
56	Synthesis, Optimization, Antifungal Activity, Selectivity, and CYP51 Binding of New 2-Aryl-3-azolyl-1-indolyl-propan-2-ols. <i>Pharmaceuticals</i> , 2020, 13, 186.	3.8	12
57	Synthesis and antimycobacterial activity of 7-O-substituted-4-methyl-2H-2-chromenone derivatives vs <i>Mycobacterium tuberculosis</i> . <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2005, 20, 109-113.	5.2	10
58	Expanding Precompetitive Multisector Collaborations to Advance Drug Development and Pharmacogenomics. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 96-101.	4.7	6
59	Unveiling the Genetic Architecture of Human Disease for Precision Medicine. <i>Clinical and Translational Science</i> , 2019, 12, 3-5.	3.1	3
60	The Effects of Genetic Mutations and Drugs on the Activity of the Thiamine Transporter, SLC19A2. <i>AAPS Journal</i> , 2021, 23, 35.	4.4	2
61	Mechanisms and genetics of drug transport. , 2022, , 213-239.		1
62	Synthesis and CYP24 Inhibitory Activity of 2-Substituted-3,4-dihydro-2H-naphthalen-1-one (Tetralone) Derivatives.. <i>ChemInform</i> , 2005, 36, no.	0.0	0
63	Pharmacogenetics of Metformin. , 2016, , 463-481.		0
64	Genome-Wide Meta-Analysis Identifies the Organic Anion-Transporting Polypeptide Gene &lt;i>SLCO1B1&lt;/i> and Statins as Modifiers of Glycemic Response to Sulfonylureas. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
65	Germline Genetic Polymorphisms Are Associated with Disease-Free Survival in Adults with Acute Myeloid Leukemia (AML): A Genomewide Association Study From the Pgrn-Riken Global Alliance.. <i>Blood</i> , 2012, 120, 2548-2548.	1.4	0
66	Response to Comment on Dawed et al. Genome-Wide Meta-analysis Identifies Genetic Variants Associated With Glycemic Response to Sulfonylureas. <i>Diabetes Care</i> 2021;44:2673â€“2682. <i>Diabetes Care</i> , 2022, 45, e82-e83.	8.6	0